UTMD Q4 EPS $1.127; FY2021 sales $49.1M, net income up 37% YoY

UTAH MEDICAL PRODUCTS INC

2021-FY EPS reported $4.04 revenue$49,054,000

Diluted EPS Q4 $1.127 (up 20.6% YoY); FY GAAP EPS $4.041, non-GAAP $4.147.
Full year revenue $49.1M (+16%); gross margin expanded to 63.0% from 60.6%.
Operating income margin 38.5% vs 32.5%; adjusted EBITDA $26.5M (54.1% of sales).
Paid $2.00/share special dividend in Dec 2021 ($7.3M) plus regular $0.285; cash $60.9M.
Management projects 2022 adjusted EBITDA ~$30M, up from prior estimate of $28M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.